FABTECH - Fabtech Tech.
📢 Recent Corporate Announcements
Fabtech Technologies Limited successfully conducted two separate investor interactions on March 10, 2026, to discuss business operations and strategic outlook. The company participated in the 'Bharat Connect Conference – Rising Stars 2026' hosted by Arihant Capital via video conferencing. Additionally, officials attended the 'Vivro Corporate Connect – Investors’ Meet 2026' physically in Mumbai. The discussions focused on market opportunities and future growth strategies based on publicly available information.
- Participated in the Bharat Connect Conference hosted by Arihant Capital on March 10, 2026.
- Attended the Vivro Corporate Connect physical meeting in Mumbai starting at 9:00 AM IST.
- Discussions covered business operations, market opportunities, and future strategic directions.
- Company confirmed that no unpublished price-sensitive information (UPSI) was shared during the meetings.
Fabtech Technologies Limited has responded to inquiries from the NSE and BSE regarding a significant spurt in trading volume and price movement. The company officially stated that there is no pending price-sensitive information or undisclosed announcements that could have triggered this activity. Management clarified that the recent volatility is purely market-driven and not linked to any internal corporate developments. The filing was made on March 11, 2026, to ensure transparency and safeguard investor interests as per SEBI regulations.
- Company responded to exchange queries regarding unusual volume on March 11, 2026
- Management confirms no undisclosed material information exists under Regulation 30
- Stock price and volume movements are attributed entirely to market forces
- Company reaffirms commitment to timely disclosure of all future price-sensitive events
Fabtech Technologies has responded to a clarification sought by the National Stock Exchange (NSE) regarding the signing of its financial results for the quarter ended December 31, 2025. The company confirmed that the results, approved on February 02, 2026, were signed by authorized personnel including Executive Director Hemant Anavkar and Non-Executive Director Amjad Arbani. The company cited SEBI Regulation 33(2)(b), which permits any board-authorized director to sign financial statements. This clarification addresses procedural queries raised by the exchange to ensure the results are officially recorded without further delay.
- NSE sought clarification on February 27, 2026, regarding the signing protocol of Q3 FY26 results.
- Company confirmed results were approved in a Board Meeting held on February 02, 2026.
- Board Resolution authorized Mr. Hemant Anavkar (ED) and Mr. Amjad Arbani (NED) to sign the results.
- The company maintains full compliance with SEBI Regulation 33(2)(b) regarding signatory requirements.
- The clarification aims to resolve the exchange's query and finalize the recording of the financial results.
Fabtech Technologies Limited has scheduled a one-on-one interaction with investors and analysts on March 12, 2026. The meeting is set to take place virtually via video conference starting at 2:30 p.m. IST. The company has explicitly stated that the discussions will be based on publicly available information and no unpublished price-sensitive information (UPSI) will be shared. This meeting is a routine part of the company's investor relations activities under SEBI regulations.
- One-on-one virtual meeting scheduled for Thursday, March 12, 2026, at 2:30 p.m. IST.
- Interaction will be conducted through video conferencing with various analysts and investors.
- Company confirms that no unpublished price-sensitive information (UPSI) will be discussed.
- The meeting is subject to change based on the exigencies of the participants or the company.
Fabtech Technologies Limited has scheduled a virtual one-on-one meeting with analysts and investors on March 12, 2026, at 2:30 p.m. IST. The interaction is intended to discuss the company's performance based on publicly available information, ensuring compliance with SEBI regulations regarding price-sensitive data. This routine engagement highlights the management's effort to maintain transparency with the investment community. No unpublished price-sensitive information (UPSI) is expected to be disclosed during this session.
- One-on-one virtual meeting scheduled for March 12, 2026, at 2:30 p.m. IST.
- Interaction will be conducted via video conference with institutional analysts and investors.
- Discussions will strictly adhere to publicly available information to avoid UPSI disclosure.
- The notification was filed under Regulation 30 of SEBI (LODR) Regulations, 2015.
Fabtech Technologies Limited has announced a virtual interaction with investors and analysts scheduled for March 10, 2026, at 4:00 p.m. IST. The company will be participating in the 'Bharat Connect Conference – Rising Stars 2026' organized by Arihant Capital. This group meeting is intended to engage with the investment community using publicly available information. No unpublished price-sensitive information is expected to be disclosed during the session.
- Investor meeting scheduled for March 10, 2026, at 4:00 p.m. IST
- Participation in the Bharat Connect Conference – Rising Stars 2026 hosted by Arihant Capital
- The interaction will be conducted via a virtual group meeting format
- Company confirms discussions will be limited to publicly available information only
Fabtech Technologies Limited has announced its participation in the CVOCA Investocraft 2026 event on February 28, 2026. The physical group meeting with investors and analysts will commence at 8:30 a.m. IST at Sahara Star, Mumbai. The company stated that discussions will be based strictly on publicly available information, ensuring no unpublished price-sensitive information is shared. This event serves as a platform for the management to engage with the broader investment community.
- Scheduled physical group meeting with investors on February 28, 2026, at 8:30 a.m. IST
- Participation in the CVOCA Investocraft 2026 event held at Sahara Star, Mumbai
- Company officials to interact with analysts and investors regarding general business outlook
- Strict adherence to sharing only publicly available information during the interaction
- Intimation provided under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations
Fabtech Technologies reported temporary softness in Q3 FY26 revenue due to shipment-based accounting, with ₹20.3 crores of revenue deferred to Q4 after material was held at the port. The company maintains a robust outstanding order book of ₹926 crores as of January 31, 2026, primarily driven by export demand in Africa and the Middle East. Management highlighted a significant 'hot lead bank' pipeline valued at approximately $455 million. The company is also streamlining its portfolio by exiting TSA Process Equipments within the current financial year to focus on its core life-sciences infrastructure platform.
- Outstanding order book reached ₹926 crores as of January 31, 2026, with a heavy focus on international markets.
- Revenue of ₹20.3 crores was deferred from Q3 to Q4 due to timing of shipments and port delays.
- Management identified a robust pipeline of potential orders (hot lead bank) worth approximately $455 million.
- Company plans to exit its investment in TSA Process Equipments within the 2025-26 financial year.
- Typical project execution timelines range from 9 to 18 months, with efforts underway to accelerate delivery.
Fabtech Technologies Limited has officially released the video recording of its earnings conference call held on February 10, 2026. The call focused on the company's unaudited financial performance for the third quarter and the nine-month period ended December 31, 2025. This disclosure provides investors with direct access to management's commentary and responses to institutional inquiries regarding the company's recent results. The recording is available on the company's website as per SEBI compliance requirements.
- Earnings conference call held on February 10, 2026, at 10:00 a.m. IST.
- Discussion covered unaudited financial results for Q3 and 9M ended December 31, 2025.
- Video recording link provided for public access and transparency.
- Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015.
Fabtech Technologies reported a strong 32.79% YoY growth in total income to ₹26,309.11 Lakhs for 9M FY26. However, the company experienced a significant contraction in profitability, with EBITDA falling 45.04% and Net Profit dropping 48.02% to ₹1,630.23 Lakhs. EBITDA margins saw a sharp decline from 21.95% to 9.08%, indicating operational cost pressures. Despite the profit dip, the company maintains a robust order book of ₹98,305 Lakhs and holds ₹20,679 Lakhs in unutilized IPO proceeds for expansion.
- Total Income increased by 32.79% YoY to ₹26,309.11 Lakhs for the nine months ended December 2025.
- Net Profit declined by 48.02% YoY to ₹1,630.23 Lakhs, with Net Profit Margin shrinking to 6.20%.
- EBITDA margins contracted significantly to 9.08% from 21.95% in the previous year.
- Order book remains strong at ₹98,305 Lakhs as of November 03, 2025.
- Unutilized IPO proceeds of ₹20,679.40 Lakhs are available for working capital and inorganic growth initiatives.
Fabtech Technologies Limited has scheduled its earnings conference call for February 10, 2026, at 10:00 AM IST to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025. The call will feature key management figures including the Promoter, CEO, and Chief Growth Officer. This session will provide investors with direct insights into the company's Q3 performance and future outlook through a management discussion and a Q&A session. The event is coordinated by AKMIL Strategic Advisors.
- Earnings call scheduled for February 10, 2026, at 10:00 AM IST.
- Focus on Unaudited Financial Results for Q3 FY26 and 9M FY26 ending December 31, 2025.
- Management participants include Promoter Mr. Aasif Khan and CEO Mr. Ashwani Singh.
- The session includes a formal management discussion followed by an interactive Q&A session.
- Call organized in collaboration with AKMIL Strategic Advisors.
Fabtech Technologies Limited has officially confirmed that there was no deviation or variation in the utilization of funds raised through its Public Issue (IPO) for the quarter ended December 31, 2025. The company successfully raised ₹230.30 crore on October 7, 2025, and the proceeds are being used as per the objects stated in the prospectus. The statement has been reviewed by the Audit Committee and is monitored by CRISIL Ratings Limited. This report provides transparency regarding the company's capital allocation and adherence to regulatory requirements.
- Total funds raised through the Public Issue (IPO) amounted to ₹2,30,29,65,305 (approx ₹230.30 crore).
- Company reported zero deviation or variation in the use of proceeds for the quarter ended December 31, 2025.
- CRISIL Ratings Limited is the appointed monitoring agency for the fund utilization.
- The Audit Committee reviewed and confirmed the statement in its meeting held on February 02, 2026.
Fabtech Technologies reported a weak Q3 FY26 with a consolidated net loss of ₹5.68 crore, a sharp reversal from the ₹20.46 crore profit in the same quarter last year. Revenue from operations declined significantly to ₹62.76 crore from ₹104.32 crore YoY, reflecting a 39.8% drop. While nine-month revenue grew to ₹252.25 crore, the net profit for the same period nearly halved to ₹16.30 crore due to rising finance and operating costs. The company also dissolved its Risk Management Committee, citing it is no longer mandatorily required under SEBI regulations.
- Consolidated Revenue for Q3 FY26 fell 39.8% YoY to ₹62.76 crore compared to ₹104.32 crore.
- Reported a Net Loss of ₹5.68 crore in Q3 FY26 versus a Net Profit of ₹20.46 crore in Q3 FY25.
- 9M FY26 Net Profit declined by 48% to ₹16.30 crore despite a 31.5% increase in 9M revenue.
- Finance costs for the nine-month period surged to ₹3.28 crore from ₹1.01 crore YoY.
- Board approved the dissolution of the Risk Management Committee, with oversight moving to the Audit Committee.
Fabtech Technologies reported a weak performance for Q3 FY26, swinging to a consolidated net loss of ₹5.68 crore from a profit of ₹20.46 crore in the same period last year. Revenue from operations saw a sharp decline of 39.8% YoY to ₹62.76 crore, while sequential revenue dropped by nearly 48% compared to Q2 FY26. The results were significantly impacted by a loss of ₹5.86 crore in its UAE-based foreign subsidiary. Despite a 31.5% revenue growth for the nine-month period ending December 2025, net profit for the same period nearly halved to ₹16.30 crore.
- Consolidated revenue for Q3 FY26 fell to ₹62.76 crore from ₹104.32 crore in Q3 FY25.
- Reported a net loss of ₹5.68 crore in Q3 FY26 against a profit of ₹20.46 crore in the previous year's quarter.
- UAE subsidiary (Fabtech Technologies LLC) dragged performance with a quarterly loss of ₹5.86 crore.
- 9M FY26 net profit declined to ₹16.30 crore from ₹31.36 crore in 9M FY25 despite higher cumulative revenue.
- Board approved the dissolution of the Risk Management Committee, citing it is no longer mandatory under SEBI regulations.
Fabtech Technologies has announced an on-site plant visit for a group of investors and analysts scheduled for February 04, 2026, in Dubai, UAE. The visit is designed to showcase the company's end-to-end turnkey execution capabilities specifically within the life sciences and healthcare sectors. This physical interaction aims to provide deeper operational insights into their international projects. The company has clarified that no unpublished price-sensitive information (UPSI) will be shared during this meeting.
- Physical group meeting with investors and analysts scheduled for February 04, 2026.
- The visit will take place at the company's units in Dubai, UAE.
- Focus on demonstrating turnkey execution capabilities in life sciences and healthcare.
- Compliance with SEBI Regulation 30 ensures transparency in investor relations.
- No unpublished price-sensitive information (UPSI) intended to be shared during the visit.
Financial Performance
Revenue Growth by Segment
Turnkey engineering solutions for life sciences grew 43.7% in FY25 to INR 322.47 Cr. Approximately 30% of revenue is derived from in-house manufactured products (Process, Air, and Water systems), while 70% comes from integrated project management and third-party equipment supply.
Geographic Revenue Split
The company operates in 62 countries with a strong presence in 22 active markets. Key growth regions include MENA (Middle East and North Africa), GCC, and ECO Zone, which are driving revenue through increased investments in local pharmaceutical self-reliance.
Profitability Margins
PAT margins improved from 12.03% in FY24 to 15.48% in FY25. However, operating margins saw a decline from 16.23% in FY24 to 12.73% in FY25 due to project mix and cost structures. H1 FY26 Net Profit stood at INR 21.98 Cr, a 101.6% YoY increase.
EBITDA Margin
EBITDA margin for H1 FY26 was 14.7%, reflecting a significant improvement from the 12.73% reported in FY25. The company targets a sustainable annual EBITDA range of 12-15% despite quarterly lumpiness in project execution.
Capital Expenditure
Fabtech follows an asset-light model and is not capital-intensive. The company successfully raised INR 230 Cr through an IPO fresh issue in October 2025, primarily to fund working capital requirements and business expansion rather than heavy manufacturing assets.
Credit Rating & Borrowing
Crisil reaffirmed ratings at 'Crisil BBB+/Stable' for long-term and 'Crisil A2' for short-term facilities. Working capital utilization averaged 70% over the 7 months ended June 2025, with an adjusted debt-to-networth ratio of 0.39x as of March 2025.
Operational Drivers
Raw Materials
Key raw materials include stainless steel, specialized components for HVAC systems, and water purification filters. Raw material costs (Cost of Material) accounted for 54.1% of total income in FY25, amounting to INR 181.86 Cr.
Import Sources
Not explicitly disclosed, but the company operates in 62 countries and sources components globally to support its international turnkey projects in regions like MENA and GCC.
Capacity Expansion
The company operates an asset-light model where revenue is driven by project engineering and design. Management stated they can double revenue (X to X+Y) with the same core team by increasing procurement and engineering oversight without significant gross block expansion.
Raw Material Costs
Cost of materials increased from INR 121.51 Cr in FY24 to INR 181.86 Cr in FY25, representing a 49.6% increase. Procurement is managed through a 'single window' model to ensure speed and compliance for pharmaceutical clients.
Manufacturing Efficiency
The company maintains ISO-certified operations with a team of 180+ members, including 94+ qualified engineers, focusing on 'execution excellence' to maintain a 9% quarterly growth trajectory.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved by leveraging the INR 904.42 Cr order book (as of July 2025), expanding the 'single window' turnkey model in emerging pharmaceutical markets, and focusing on nations seeking 'medicinal independence' through local manufacturing capacity.
Products & Services
Turnkey pharmaceutical plants, Cleanrooms, HVAC systems, Water for Injection (WFI) systems, Pure Water distribution systems, and Precision Process equipment for biotech and healthcare.
Brand Portfolio
FABTECH, FABL International Technologies, FT Institutions, Fabtech Technologies LLC, FTS Cleanrooms Systems.
New Products/Services
The company is expanding into high-margin capex projects and integrated automation for life sciences, aiming for a 9% sequential growth in the project pipeline.
Market Expansion
Targeting deeper penetration in MENA, GCC, and ECO Zone regions where governments are subsidizing healthcare infrastructure to achieve self-reliance.
Strategic Alliances
The group consolidates operations with subsidiaries like FABL International and FTS Cleanrooms Systems to provide a unified global engineering service.
External Factors
Industry Trends
The industry is shifting toward 'local medicinal independence' in emerging markets. Global pharmaceutical engineering is growing as companies upgrade facilities to meet stringent USFDA and EU GMP compliance standards.
Competitive Landscape
Competes primarily with European engineering firms. Fabtech positions itself as a more cost-effective, integrated alternative with faster execution speeds.
Competitive Moat
Moat is built on a 3-decade legacy, in-house manufacturing of critical Air/Water/Process systems (30% of project value), and a 'single window' model that ensures faster regulatory compliance than Western competitors.
Macro Economic Sensitivity
Highly sensitive to pharmaceutical industry capex cycles and government healthcare spending in emerging markets.
Consumer Behavior
Increased demand for biotech and life sciences infrastructure following global health crises, driving a shift toward more complex, automated manufacturing facilities.
Geopolitical Risks
Exposure to volatile international markets; however, management mitigates this by diversifying across multiple regions so that if one market slows, others (like the ECO zone) can compensate.
Regulatory & Governance
Industry Regulations
Operations must comply with global pharmaceutical standards including USFDA, EU GMP, Saudi FDA, and UK MHRA. Failure to meet these standards would halt project handovers.
Taxation Policy Impact
Effective tax rate for FY25 was approximately 23.1% (INR 13.98 Cr tax on INR 60.43 Cr PBT).
Risk Analysis
Key Uncertainties
Quarterly earnings volatility due to the 'lumpy' nature of project-based billing, which can see margins swing from 8% to 25% between quarters.
Geographic Concentration Risk
Significant revenue concentration in emerging markets (MENA/GCC), making the company vulnerable to regional geopolitical instability.
Third Party Dependencies
70% of turnkey project components are sourced from third-party vendors, creating risks related to quality control and supply chain delays.
Technology Obsolescence Risk
Risk of shifting to advanced biotech manufacturing processes; mitigated by in-house design and engineering teams focusing on precision process systems.
Credit & Counterparty Risk
High working capital intensity with a focus on debtor collection as a key rating sensitivity factor. Cash and bank balance stood at INR 35.19 Cr as of March 2025.